Zofenozid: possibilities and special place in blood pressure control and cardioprotection in patients with ischemic heart disease

The fixed combination of zofenopril and hydrochlorothiazide (Zofenozid) is a modern approach to the treatment of arterial hypertension, which combines effective blood pressure control with multi-vector cardio- and vasoprotection. Due to the synergy of inhibition of the renin-angiotensin-aldosterone system and the diuretic component, the drug provides a stable 24-hour antihypertensive effect, increases adherence to therapy and corresponds to the modern strategy of early use of fixed combinations in patients with high cardiovascular risk. Of particular clinical importance is the use of zofenopril as a representative of angiotensin-converting enzyme inhibitors with pronounced pleiotropic properties, which provides additional antioxidant, endothelioprotective and anti-ischemic effects. In patients with a combination of arterial hypertension and ischemic heart disease, Zofenozid is considered a rational therapeutic option, capable of influencing not only hemodynamic parameters, but also key pathogenetic mechanisms of cardiovascular remodeling. Its use is associated with improved vascular function, reduced inflammatory load and potential modification of the atherosclerotic process, which makes the drug a reasonable component of a long-term secondary prevention strategy in patients at high and very high risk.